The pharmacotherapy of schizophrenia is currently dominated by atypical antipsychotics that primarily target dopaminergic signalling, the dysregulation of which has long been considered to have a ...

Researchers from China Pharmaceutical University and Jiangsu Nhwa Pharmaceutical Co. Ltd. have synthesized azetidine-containing compounds acting as muscarinic M4 receptor positive allosteric ...

People who suffer from the autoimmune disease myasthenia gravis experience muscle weakness that can affect any of the muscles we use to blink, smile or even move our body around.

The crown jewel of the acquisition was seen as emraclidine, an allosteric modulator that selectively targets the muscarinic acetylcholine 4 receptor subtype. It was seen as a potential next ...

In the case of myasthenia gravis, the body produces autoantibodies that target acetylcholine receptors (AChRs), which are essential triggers for normal muscle contraction functions. Medications ...

Muscarinic receptors are involved with neurotransmission via acetylcholine and glutamate, and are hypothesised to be dysfunctional in schizophrenia. Most drugs developed to treat schizophrenia to ...

The drug – a selective muscarinic M4 receptor positive allosteric modulator (PAM) – is designed to have limited effect on dopamine neurotransmission, a mechanism thought to contribute to ...